Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?

International Journal of Pharmaceutics

Volumn 468, Issue 1-2, 2014, Pages 15-25

  Li, Chunlei ^a   Li, Yanhui ^b   Gao, Yuqing ^b   Wei, Na ^b   Zhao, Xi ^b   Wang, Caixia ^b,c,d   Li, Yongfeng ^b,c,d   Xiu, Xian ^b,c,d   Cui, Jingxia ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

^d State Key Lab of Novel Pharmaceutical Preparations and Excipients   (China)

Author keywords

Albumin; Efficacy; Nanoparticles; Paclitaxel; Pharmacokinetics; Stability

Indexed keywords

ALBUMIN; ALBUMIN NANOPARTICLE; NANOCARRIER; PACLITAXEL; UNCLASSIFIED DRUG; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DRUG CARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER GROWTH; CONTROLLED STUDY; CROSS LINKING; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TISSUE HOMOGENATE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; MOUSE; NANOTECHNOLOGY; PATHOLOGY; PERMEABILITY; PHARMACEUTICS; PROCEDURES; PROSTATIC NEOPLASMS; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR CELL LINE; WISTAR RAT;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG STABILITY; INJECTIONS, INTRAVENOUS; MALE; MICE; NANOPARTICLES; NANOTECHNOLOGY; PACLITAXEL; PERMEABILITY; PROSTATIC NEOPLASMS; RATS, WISTAR; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 84899438907     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.04.010     Document Type: Article

References (26)

1. T.M. Allen Long-circulating (sterically stabilized) liposomes for targeted drug delivery Trends in Pharmacological Sciences 15 1994 215 220 (Pubitemid 24210725)
2. T.M. Allen Liposomes. Opportunities in drug delivery Drugs 54 Suppl. 4 1997 8 14 (Pubitemid 27487790)
3. J. Cui, C. Li, W. Guo, Y. Li, C. Wang, L. Zhang, L. Zhang, Y. Hao, and Y. Wang Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Journal of Controlled Release 118 2007 204 215 (Pubitemid 46350710)
4. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems Journal of Controlled Release 157 2012 168 182
5. R. Fanciullino, J. Ciccolini, and G. Milano Expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs Critical Reviews in Oncology/Hematology 88 2013 504 513
6. M. Foote Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel Biotechnology Annual Review 13 2007 345 357 (Pubitemid 47387129)
7. Q. Fu, J. Sun, W. Zhang, X. Sui, Z. Yan, and Z. He Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery Recent Patents on Anti-Cancer Drug Discovery 4 2009 262 272
8. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clinical Pharmacokinetics 42 2003 419 436 (Pubitemid 36649037)
9. H.J. Guchelaar, C.H. ten Napel, E.G. de Vries, and N.H. Mulder Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review Clinical Oncology (Royal College of Radiologists) 6 1994 40 48 (Pubitemid 24088839)
10. R. Hájek, J. Vorlicek, and M. Slavik Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview Neoplasma 43 1996 141 154 (Pubitemid 26229348)
11. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Advanced Drug Delivery Reviews 60 2008 876 885
12. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery Journal of Controlled Release 161 2012 429 445
13. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles Journal of Controlled Release 132 2008 171 183
14. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, and D. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles International Journal of Pharmaceutics 257 2003 169 180 (Pubitemid 36507043)
15. K. Langer, M.G. Anhorn, I. Steinhauser, S. Dreis, D. Celebi, N. Schrickel, S. Faust, and V. Vogel Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation International Journal of Pharmaceutics 347 2008 109 117 (Pubitemid 350180317)
16. C. Li, J. Cui, C. Wang, J. Wang, Y. Li, L. Zhang, L. Zhang, W. Guo, and Y. Wang Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone International Journal of Pharmaceutics 362 2008 60 66
17. P. Ma, and R.J. Mumper Paclitaxel nano-delivery systems: a comprehensive review Journal of Nanomedicine and Nanotechnology 4 2013 1000164
18. A. Maham, Z. Tang, H. Wu, J. Wang, and Y. Lin Protein-based nanomedicine platforms for drug delivery Small 5 2009 1706 1721
19. A. Moreno-Aspitia, and E.A. Perez Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer Future Oncology 1 2005 755 762
20. S. Rhaese, H. von Briesen, H. Rübsamen-Waigmann, J. Kreuter, and K. Langer Human serum albumin-polyethylenimine nanoparticles for gene delivery Journal of Controlled Release 92 2003 199 208 (Pubitemid 37130132)
21. A. Sharma, and R.M. Straubinger Novel taxol formulations: preparation and characterization of taxol-containing liposomes Pharmaceutical Research 11 1994 889 896 (Pubitemid 24210627)
22. S. Strieth, M.E. Eichhorn, A. Werner, B. Sauer, M. Teifel, U. Michaelis, A. Berghaus, and M. Dellian Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin Clinical Cancer Research 14 2008 4603 4611
23. B. von Storp, A. Engel, A. Boeker, M. Ploeger, and K. Langer Albumin nanoparticles with predictable size by desolvation procedure Journal of Microencapsulation 29 2012 138 146
24. D.A. Yardley nab-Paclitaxel mechanisms of action and delivery Journal of Controlled Release 170 2013 365 372
25. H.K. Yoon, A. Ray, Y.E. Lee, G. Kim, X. Wang, and R. Kopelman Polymer-protein hydrogel nanomatrix for stabilization of indocyanine green towards targeted fluorescence and photoacoustic bio-imaging Journal of Materials Chemistry B Home-Materials for Biology and Medicine 1 2013 5611 5619
26. J.A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation European Journal of Pharmaceutics and Biopharmaceutics 59 2005 177 187 (Pubitemid 39573451)